News | News By Subject | News by Disease News By Date | Search News

Uveitis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News

News from Around the Web

Press Releases
AbbVie (ABBV)'s Research And Commitment To Helping People Living With Rheumatologic Diseases Highlighted At The Annual European Congress Of Rheumatology (EULAR 2016)     6/2/2016
AbbVie (ABBV)'s HUMIRA (Adalimumab) Receives CHMP Positive Opinion To Treat Certain Forms Of Non-Infectious Uveitis, A Disease That Can Severely Impact Vision[1]     5/27/2016
EyeGate Pharma Receives Additional Milestone Payment From Valeant (VRX) For EGP-437     3/2/2016
EyeGate Pharma Signs Licensing Agreement With Valeant (VRX) For EGP-437 Combination Product In Uveitis     7/10/2015
pSivida Corp (PSDV) Completes Targeted Enrollment Of Phase III Trial Of Medidur For Posterior Uveitis     3/26/2015
AbbVie (ABBV) Receives Orphan Drug Designation For HUMIRA® (Adalimumab) From The FDA For The Investigational Treatment Of Certain Forms Of Non-Infectious Uveitis     5/21/2014
pSivida Corp (PSDV) Announces Interim Data From Investigator-Sponsored Uveitis Study     7/11/2013
EyeGate Pharma's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis     4/9/2013
pSivida Corp (PSDV) Receives FDA Clearance for Pivotal Trials for Injectable Sustained-Release Micro-Insert to Treat Uveitis     7/19/2012
pSivida Corp (PSDV) Announces Enrollment of First Patient in Uveitis Trial     6/28/2012
Santen, Inc. Announces FDA Orphan Drug Status for Sirolimus (DE-109)     11/10/2011
Santen, Inc. Announces European Medicines Evaluation Agency Orphan Drug Status for Sirolimus (DE-109)     9/8/2011
Enzo Biochem (ENZ) Initiates Clinical Trial for Treatment of Uveitis at National Institutes of Health (NIH)     10/4/2010
Lux Biosciences Receives Complete Response Letter from FDA for Luveniq(TM)     8/4/2010
Lux Biosciences Completes Enrollment in LUMINATE Pivotal Trial Program for Novel Uveitis Therapy, LUVENIQ(TM)     6/25/2008

//-->